Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SAN FRANCISCO, July 31, 2017 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the second quarter of 2017 on Monday, August 7, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 45181364#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 45181364
About FibroGen
FibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. [email protected] (415) 978-1433
